British biotechs unveil new partnership deals

Tuesday 14 September 1999 00:02 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

THE RECOVERY of the UK biotechnology sector continued yesterday as two companies unveiled major partnerships.

Vanguard Medica, the pounds 80m migraine and psoriasis researcher, has secured an agreement with Menarini, a privately owned Italian company, to distribute its frovatriptan treatment for acute migraine in Europe. Meanwhile SkyePharma, which is capitalised at pounds 283m and modifies other company's drugs, has struck a deal with SmithKline Beecham to tweak its Requip treatment for Parkinson's disease.

Frovatriptan is expected to be launched in Europe by next June, with the US launch following shortly afterwards.

SkyePharma's tie-up with SmithKline sees it receiving milestone payments and royalties, along with an $8m investment in SkyePharma's equity. SkyePharma is to transform Requip from a three-times-a-day to a once- daily treatment.

Vanguard's shares closed up 7.5p at 242.5p. SkyePharma closed 2.5p ahead at 60p.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

British biotechs unveil new partnership deals

Join our commenting forum

Thank you for registering